Mostrar el registro sencillo del ítem
Artículo
ECP versus ruxolitinib in steroid-refractory acute GVHD – a retrospective study by the EBMT transplant complications working party
dc.creator | Penack, Olaf | es |
dc.creator | Peczynski, Christophe | es |
dc.creator | Boreland, William | es |
dc.creator | Lemaitre, Jessica | es |
dc.creator | Afanasyeva, Ksenia | es |
dc.creator | Kornblit, Brian | es |
dc.creator | Pérez Simón, José Antonio | es |
dc.creator | Peric, Zinaida | es |
dc.date.accessioned | 2024-04-30T13:25:56Z | |
dc.date.available | 2024-04-30T13:25:56Z | |
dc.date.issued | 2023-12-11 | |
dc.identifier.citation | Penack, O., Peczynski, C., Boreland, W., Lemaitre, J., Afanasyeva, K., Kornblit, B.,...,Peric, Z. (2023). ECP versus ruxolitinib in steroid-refractory acute GVHD – a retrospective study by the EBMT transplant complications working party. Frontiers In Immunology, 14, 1283034. https://doi.org/10.3389/fimmu.2023.1283034. | |
dc.identifier.issn | 1664-3224 | es |
dc.identifier.uri | https://hdl.handle.net/11441/157357 | |
dc.description.abstract | Introduction: Extracorporal Photophoresis (ECP) is in clinical use for steroidrefractory and steroid-dependent acute GVHD (SR-aGVHD). Based on recent Phase-III study results, ruxolitinib has become the new standard of care for SRaGVHD. Our aim was to collect comparative data between ruxolitinib and ECP in SR-aGVHD in order to improve the evidence base for clinical decision making. Methods: We asked EBMT centers if they were willing to participate in this study by completing a data form (Med-C) with detailed information on GVHD grading, -therapy, -dosing, -response and complications for each included patient. Results: 31 centers responded positively (14%) and we included all patients receiving alloSCT between 1/2017-7/2019 and treated with ECP or ruxolitinib for SR-aGVHD grades II-IV from these centers. We identified 53 and 40 patients with grades II-IV SR-aGVHD who were treated with ECP and ruxolitinib, respectively. We performed multivariate analyses adjusted on grading and type of SR-aGVHD (steroid dependent vs. refractory). At day+90 after initiation of treatment for SR-aGVHD we found no statistically significant differences in overall response. The odds ratio in the ruxolitinib group to achieve overall response vs. the ECP group was 1.13 (95% CI = [0.41; 3.22], p = 0.81). In line, we detected no statistically significant differences in overall survival, progressionfree survival, non-relapse mortality and relapse incidence. Discussion: The clinical significance is limited by the retrospective study design and the current data can’t replace prospective studies on ECP in SR-aGVHD. However, the present results contribute to the accumulating evidence on ECP as an effective treatment option in SR-aGVHD. | es |
dc.format | application/pdf | es |
dc.format.extent | 9 p. | es |
dc.language.iso | eng | es |
dc.publisher | Frontiers Media S.A. | es |
dc.relation.ispartof | Frontiers In Immunology, 14, 1283034. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | ECP | es |
dc.subject | GvHD | es |
dc.subject | Ruxolinitib | es |
dc.subject | Steroid-refractory | es |
dc.subject | Allogeneic stem cell transplantation | es |
dc.title | ECP versus ruxolitinib in steroid-refractory acute GVHD – a retrospective study by the EBMT transplant complications working party | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1283034/full | es |
dc.identifier.doi | 10.3389/fimmu.2023.1283034 | es |
dc.journaltitle | Frontiers In Immunology | es |
dc.publication.volumen | 14 | es |
dc.publication.initialPage | 1283034 | es |